Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Aldoxorubicin · INNO-206

Small molecule · Cytotoxic, directed at DNA · developed by ImmunityBio

Phase 2 Most advanced trial

IBRX Developer

3 Registered trials

What is Aldoxorubicin?

Aldoxorubicin is a prodrug of the anthracycline doxorubicin that binds the cysteine-34 position of albumin after intravenous administration. The hydrazone linker is cleaved in the acidic environment of tumors, releasing doxorubicin, which intercalates DNA and induces apoptosis. It is studied in pancreatic cancer, non-small cell lung cancer, chordoma and unresectable malignant neoplasm.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: INNO-206
Drug type: Small molecule
Targets: DNA
Mechanism: Cytotoxic, directed at DNA
Pathways: DNA synthesis inhibition, apoptosis
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: C28MV4IM0B

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04390399	Phase 2	Pancreatic Cancer	Active not recruiting	IBRX
NCT03647423	Phase 1/2	Chordoma	Withdrawn	IBRX
NCT03574649	Phase 2	Non Small Cell Lung Cancer	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pancreatic CancerChordomaNon Small Cell Lung CancerUnresectable Malignant Neoplasm

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 CD19 t-haNK Phase 2 ETBX-021 Phase 1/2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2 GI-4000 Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind Aldoxorubicin

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z